Lite Strategy (LITS) Stock Price

Lite Strategy Price

NASDAQ·CLOSED
0.91
​
Market closed

Over the last 17 years Lite Strategy grew revenue by 31.1% annually, reaching 65.30 M USD. For Lite Strategy, the net margin of 27.2% is up versus -169.9% a few years ago. At today's price the dividend yield works out to roughly 1.92%.

Lite Strategy stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lite Strategy business model & stock analysis

MEI Pharma, Inc. develops cancer therapies, focusing on clinical drug candidates including Pracinostat, ME-344, and ME-401. Pracinostat, an HDAC inhibitor for hematologic diseases like AML and MDS, has undergone Phase I and II trials. ME-344 targets mitochondrial components in rapidly proliferating cells, while ME-401 inhibits PI3K delta for hematologic cancer treatment. The company generates revenue through clinical development and potential future drug sales, targeting oncology markets with its pipeline of cancer therapies. The firm's products are developed for specific cancer indications, with Pracinostat tested in advanced hematologic malignancies and solid tumors. ME-344 and ME-401 address unmet needs in mitochondrial and PI3K delta pathways, respectively. MEI Pharma's revenue model relies on clinical trial progress and future commercialization of these therapies, aiming to secure partnerships or direct sales in oncology. MEI Pharma's portfolio includes three clinical drug candidates, each targeting distinct cancer mechanisms. Pracinostat is advanced in trials for AML and MDS, while ME-344 and ME-401 are in development for broader cancer applications. The company monetizes through potential drug approvals and sales, with a focus on hematologic cancers and solid tumor markets.

Frequently asked questions about Lite Strategy

6 analysts currently rate the Lite Strategy stock: 0 recommend buying, 3 holding and 3 selling.

Converted at the current exchange rate, the Lite Strategy share trades at 0.82 EUR (0.91 USD).

The Lite Strategy share (LITS) is listed on 3 stock exchanges, including: NASDAQ (MEIP), London (0JW9.L), Frankfurt (MMIA.F).

The revenue cannot currently be calculated for Lite Strategy.

The profit of Lite Strategy is -71.15 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Lite Strategy is currently -0.44. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Lite Strategy stock.

The P/S cannot be calculated for Lite Strategy currently.

The Eulerpool Quality Score for Lite Strategy is 1/10.

The ISIN of Lite Strategy is US55279B3015. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Lite Strategy is A1KATX. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Lite Strategy is LITS. The ticker symbol is used to trade Lite Strategy shares on the stock exchange.

Fair ValueTerminal
0.77 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Dec 18, 2003
ISIN
US55279B3015
Cusip
55279B202
Sedol
B978SV6
Market capitalization
33.46 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2027
-0.55
P/Ee 2028
-0.55
P/S
P/Se
1.26
EV/EBIT
—
P/B Ratio
0.80
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-170.94 %
Last updated Nov 15, 2026, 3:37 AM

Lite Strategy Peer Group

Lite Strategy Ticker

FRANKFURT · MMIA.FLONDON · 0JW9.LNASDAQ · MEIP